2.33
전일 마감가:
$2.48
열려 있는:
$2.46
하루 거래량:
1.40M
Relative Volume:
0.88
시가총액:
$173.21M
수익:
$6.96M
순이익/손실:
$-46.51M
주가수익비율:
-13.58
EPS:
-0.1716
순현금흐름:
$-37.99M
1주 성능:
-17.96%
1개월 성능:
-17.96%
6개월 성능:
-42.89%
1년 성능:
-26.27%
Perspective Therapeutics Inc Stock (CATX) Company Profile
명칭
Perspective Therapeutics Inc
전화
509-375-1202
주소
350 Hills Street, Suite 106, Richland
CATX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
CATX
Perspective Therapeutics Inc
|
2.33 | 184.36M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-10 | 개시 | BTIG Research | Buy |
| 2025-03-13 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-01 | 개시 | Wedbush | Outperform |
| 2024-09-25 | 개시 | Truist | Buy |
| 2024-07-25 | 개시 | BofA Securities | Buy |
| 2024-05-09 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Analyzing Carlsmed (NASDAQ:CARL) and Perspective Therapeutics (NASDAQ:CATX) - Defense World
Aug Momentum: Is Perspective Therapeutics Inc part of any major indexRate Hike & Community Supported Trade Ideas - baoquankhu1.vn
CEO Moves: Is Perspective Therapeutics Inc part of any major indexMarket Performance Recap & Weekly Return Optimization Plans - baoquankhu1.vn
Critical Contrast: Perspective Therapeutics (NASDAQ:CATX) and Shoulder Innovations (NYSE:SI) - Defense World
Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals - TradingView — Track All Markets
Perspective Therapeutics (NASDAQ:CATX) Receives “Buy” Rating from BTIG Research - Defense World
BTIG Reiterates 'Buy' Rating for Perspective Therapeutics (CATX) with $14 PT | CATX Stock News - GuruFocus
Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research - MarketBeat
Short Covering: Can Perspective Therapeutics Inc generate free cash flowEarnings Overview Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Perspective Therapeutics outlines 2026 clinical and manufacturing priorities - TipRanks
Perspective Therapeutics Provides Business Updates and Strategic Priorities - TradingView — Track All Markets
Perspective Therapeutics Provides Business Updates and - GlobeNewswire
How Perspective Therapeutics Inc. stock benefits from global expansionPerformance Line Overview & walk-ready comfort choices - Улправда
Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data - TipRanks
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium - The Manila Times
Will Perspective Therapeutics Inc. stock attract ESG investorsEarnings Recap Summary & Weekly High Potential Stock Alerts - Улправда
Why Perspective Therapeutics Inc. stock could see breakout soonQuarterly Earnings Report & Verified Swing Trading Watchlists - Улправда
Published on: 2026-01-08 23:03:38 - Улправда
Will Perspective Therapeutics Inc. stock continue upward momentum2025 Biggest Moves & Reliable Entry Point Alerts - Улправда
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Why Perspective Therapeutics Inc. stock remains a top recommendationFederal Reserve Announcements & Investor Community Interactions - bollywoodhelpline.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 0.4%Should You Buy? - MarketBeat
Market Review: Will Perspective Therapeutics Inc stock continue upward momentumTrend Reversal & Risk Adjusted Buy and Sell Alerts - moha.gov.vn
Perspective Therapeutics (FRA:AAJ0) EV-to-OCF : -0.36 (As of Dec. 26, 2025) - GuruFocus
Aug Decliners: How Perspective Therapeutics Inc AAJ0 stock benefits from digital adoption2025 Stock Rankings & Daily Stock Trend Watchlist - moha.gov.vn
Perspective Therapeutics Inc Stock Analysis and ForecastRisk Management Strategies & Affordable Portfolio Tips - earlytimes.in
Can Perspective Therapeutics Inc. stock resist market sell offsWeekly Investment Recap & Weekly Momentum Picks - Улправда
Aug EndMonth: What market sentiment indicators show for Perspective Therapeutics Inc. (AAJ0) stockWeekly Profit Recap & Proven Capital Preservation Methods - Улправда
Perspective Therapeutics Earnings Notes - Trefis
How Perspective Therapeutics Inc. stock valuations compare to rivalsMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Published on: 2025-12-20 05:01:39 - Улправда
Market Review: What market sentiment indicators show for Perspective Therapeutics Inc. (AAJ0) stockQuarterly Growth Report & Low Risk High Win Rate Stock Picks - Улправда
Trading Recap: How Perspective Therapeutics Inc. stock valuations compare to rivals2025 Support & Resistance & AI Powered Market Trend Analysis - Улправда
Is Perspective Therapeutics Inc. stock in correction or buying zone2025 Fundamental Recap & Growth Focused Stock Reports - DonanımHaber
How Perspective Therapeutics Inc. (AAJ0) stock benefits from digital adoptionInsider Selling & Precise Trade Entry Recommendations - DonanımHaber
How Perspective Therapeutics Inc. stock compares to market leadersEarnings Growth Report & Community Supported Trade Ideas - DonanımHaber
Should I buy Perspective Therapeutics Inc. stock before earnings seasonJuly 2025 Spike Watch & Smart Investment Allocation Insights - Улправда
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Perspective Therapeutics, Inc. (CATX) 6.37% in After-hours: Stock Rises Amid Increased Investor Engagement - Stocks Telegraph
EV Market: How strong is Perspective Therapeutics Inc stock earnings growthTrade Signal Summary & Precise Buy Zone Identification - moha.gov.vn
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages - Defense World
Perspective Therapeutics Inc (CATX) Performance and Fundamentals Dashboard tells a completely different story - Setenews
What Is the Future of Remi Edelstahl Tubulars Limited Stock Expert Projections ExplainedCapital Gains Strategies & Maximize Gains Professionally - earlytimes.in
DHP India Limited Included in Top Momentum ScanRetail Trading Trends & Consistent Double Returns - earlytimes.in
What analysts say about Perspective Therapeutics Inc AAJ0 stockMorning Star Patterns & Download Your Free Wealth Map PDF - earlytimes.in
Affinity Asset Advisors LLC Decreases Holdings in Perspective Therapeutics, Inc. $CATX - Defense World
Perspective Therapeutics (NASDAQ: CATX) sees FMR disclose 0.4% stake - Stock Titan
Can Perspective Therapeutics Inc. stock sustain breakout momentumQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - Newser
CATX SEC FilingsPerspective Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Perspective Therapeutics Inc (CATX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Perspective Therapeutics Inc 주식 (CATX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Williamson Robert F III | Director |
Nov 12 '25 |
Buy |
2.10 |
9,498 |
19,946 |
9,864 |
| Spoor Johan M. | Chief Executive Officer |
Mar 28 '25 |
Buy |
2.24 |
22,026 |
49,384 |
59,383 |
| Spoor Johan M. | Chief Executive Officer |
Mar 28 '25 |
Buy |
2.21 |
4,650 |
10,288 |
4,650 |
| Williamson Robert F III | Director |
Mar 31 '25 |
Buy |
2.14 |
38,145 |
81,775 |
108,982 |
| Williamson Robert F III | Director |
Mar 28 '25 |
Buy |
2.27 |
22,192 |
50,376 |
70,837 |
| Graham Juan | Chief Financial Officer |
Mar 28 '25 |
Buy |
2.25 |
33,333 |
74,946 |
35,354 |
| Woods Lori A | Director |
Mar 31 '25 |
Buy |
2.13 |
23,475 |
49,999 |
183,460 |
자본화:
|
볼륨(24시간):